Documents
This page features supporting documents and evidence for current USCAST STIC. This includes formal rationale documents, links to publications describing the rationale behind STIC, and when appropriate slide presentations from our annual meetings. Additionally, any position papers or organizational statement publications can be found at the bottom of this page.
Aminoglycosides
Re-Evaluation of Aminoglycoside
In Vitro Susceptibility Test Criteria
Sujata Bhavnani, Pharm. D.
Vice Chair, USCAST
Aminoglycoside In Vitro Susceptibility Test Interpretation Criteria Evaluations
Version 1.3, 2019
DOWNLOAD
Fluoroquinolones
Polymyxins
Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)
USCAST
VIEW
Cephalosporins and Aztreonam Against Enterobacterales and P. aeruginosa
Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam
VIEW
Piperacillin-tazobactam Against Enterobacterales
Piperacillin/Tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations From the United States Committee on Antimicrobial Susceptibility Testing
VIEW
USCAST Position Statements
Old in vitro antimicrobial breakpoints are misleading stewardship efforts, delaying adoption of innovative therapies, and harming patients
VIEW
Reanalysis of cefazolin surrogate susceptibility breakpoints utilized as guidances for oral cephalosporin treatments of uncomplicated urinary tract infections: caution concerning application to cefadroxil
VIEW